Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Druss who wrote (2161)	7/14/1999 2:14:00 PM
From: out_of_the_loop	Respond to of 10293

Dear Druss: I know that it was a double-blinded study and that only Zicam and placebo were tested. I am very well-acquainted with the NEJM's standards. Since the other info (other than the Dr. Seidman comment) is not public, it would be inappropriate for me to make any other point about the study since I am not privy to see it in toto and read it. We will all have to wait for that. I do know that the results were presented at an international pharmacologic seminar in Corfu, Greece, earlier this year and were well-received. I do know the p value was <0.001. I am sure that 2 USC Ph.D.'s know the rudiments of sample size, etc. to make such claims before they submit a study. They are in this for the long haul and do not care what happens to the stock today, tomorrow or next week - and, although they have to make business decisions, are not naive enough to try to snow the NEJM. Your questions are good ones and there has to be some trust in the experience of the individuals who developed the product. Again, their motivations go beyond the daily stock price and getting the study out "fast" without regard to quality or consequence of such disregard. I wish I could tell you more but I cannot at this point. Regards, Howard